Floatz Rating
B63/100
Confidence
Indicative
Sponsor
UroGen Pharma Ltd.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05874921CT.gov uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | — | Recruiting | — | — | — |
NCT04006691CT.gov Efficacy and Safety of UGN-101 in Recurrent Patients | — | Withdrawn | — | — | — |
NCT02793128CT.gov The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Transitional Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Muamycin (this asset) | UroGen Pharma Ltd. | P3 | B · 63 |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Astellas Pharma Global Development, Inc. | P2 | BB |
| Pembrolizumab | Carisma Therapeutics Inc | P1/2 | B |
| Brivanib | Bristol-Myers Squibb | P2 | B |
| Vinflunine | Bristol-Myers Squibb | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Astellas Pharma Global Development, Inc. | P1/2 | B |
| Carboplatin | Astellas Pharma Global Development, Inc. | P1/2 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
+11 more in the Transitional Cell Carcinoma cohort
Other indications for Muamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Carcinoma | — | P3 | BB · 67 |
| Appendix Carcinoma | — | P3 | BB · 67 |
| Peritoneal Carcinomatosis | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Astellas Pharma Global Development, Inc.BB
- PembrolizumabCarisma Therapeutics IncB
- BrivanibBristol-Myers SquibbB
- VinflunineBristol-Myers SquibbB
- Cis-Diamminedichloroplatinum IiAstellas Pharma Global Development, Inc.B
Citation
Floatz Terminal. Muamycin in Transitional Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/muamycin-transitional-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →